Overview

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

Status:
Completed
Trial end date:
2014-06-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to provide pertinent information to enable decisions regarding the developability of LHW090 for use in patients with chronic renal insufficiency, including a comparison of the potential risk-benefit ratio of several doses of the study drug to enable optimal doses to be tested in later studies.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals